Imzokitug clinical trials
Also written BMS-986340.
How each study uses imzokitug has had a first review. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the imzokitug studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 2
Bristol-Myers Squibb (2) · Mayo Clinic (1) · M.D. Anderson Cancer Center (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test imzokitug.
Studies
Open first, then newest update. How each study uses imzokitug has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 2Bristol-Myers SquibbNCT07680764Added to pumitamig and chemotherapy in first-line lung cancerWritten as ImzokitugReport a problem
- BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic AdenocarcinomaRecruitingPhase 2Mayo ClinicNCT07226856Written as ImzokitugReport a problem
- A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid TumorsRecruitingPhase 1/2Bristol-Myers SquibbNCT04895709Written as BMS-986340Report a problem
- Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal CancerSuspendedPhase 2M.D. Anderson Cancer CenterNCT07011550Written as BMS-986340Report a problem
Tested with established drugs · 3 — they are given beside it
- BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic AdenocarcinomaRecruitingPhase 2Mayo ClinicNCT07226856Written as ImzokitugReport a problem
- A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid TumorsRecruitingPhase 1/2Bristol-Myers SquibbNCT04895709Written as BMS-986340Report a problem
- Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal CancerSuspendedPhase 2M.D. Anderson Cancer CenterNCT07011550Written as BMS-986340Report a problem
Tested in a combination · 1 — another drug in the study is under test too
- A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 2Bristol-Myers SquibbNCT07680764Added to pumitamig and chemotherapy in first-line lung cancerWritten as ImzokitugReport a problem
Codes
What other systems call imzokitug · ClinicalTrials.gg INT017091
- UNII (FDA) KS4YMP5WRHIMZOKITUGOne source FDA
- NCI Thesaurus C179913ImzokitugOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | KS4YMP5WRH | IMZOKITUG | One source FDA |
| NCI Thesaurus | C179913 | Imzokitug | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.